Distinct Pathways of Humoral and Cellular Immunity Induced with the Mucosal Administration of a Nanoemulsion Adjuvant


J Immunol published online 14 February 2014
http://www.jimmunol.org/content/early/2014/02/14/jimmunol.1301424

Supplementary Material http://www.jimmunol.org/content/suppl/2014/02/14/jimmunol.1301424.DCSupplemental

Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription

Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Author Choice Freely available online through The Journal of Immunology Author Choice option

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Distinct Pathways of Humoral and Cellular Immunity Induced with the Mucosal Administration of a Nanoemulsion Adjuvant

Anna U. Bielinska,*† Paul E. Makidon,† Katarzyna W. Janczak,*† Luz P. Blanco,*† Benjamin Swanson,*† Douglas M. Smith,*† Tiffany Pham,† Zsuzsanna Szabo,† Jolanta F. Kukowska-Latillo,*† and James R. Baker, Jr.*†

Nasal administration of an oil-in-water nanoemulsion (NE) adjuvant W805EC produces potent systemic and mucosal, Th-1– and Th-17–balanced cellular responses. However, its molecular mechanism of action has not been fully characterized and is of particular interest because NE does not contain specific ligands for innate immune receptors. In these studies, we demonstrate that W805EC NE adjuvant activates innate immunity, induces specific gene transcription, and modulates NF-κB activity via TLR2 and TLR4 by a mechanism that appears to be distinct from typical TLR agonists. Nasal immunization with NE-based vaccine showed that the TLR2, TLR4, and MyD88 pathways and IL-12 and IL-12Rβ1 expression are not required for an Ab response, but they are essential for the induction of balanced Th-1 polarization and Th-17 cellular immunity. NE adjuvant induces MHC class II, CD80, and CD86 costimulatory molecule expression and dendritic cell maturation. Further, upon immunization with NE, adjuvant mice deficient in the CD86 receptor had normal Ab responses but significantly reduced Th-1 cellular responses, whereas animals deficient in both CD80 and CD86 or lacking CD40 failed to produce either humoral or cellular immunity. Overall, our data show that intranasal administration of Ag with NE induces TLR2 and TLR4 activation along with a MyD88-dependent Ab response and a MyD88-dependent Th-1 and Th-17 cell–mediated immune response. These findings suggest that the unique properties of NE adjuvant may offer novel opportunities for understanding previously unrecognized mechanisms of immune activation important for generating effective mucosal and systemic immune responses. The Journal of Immunology, 2014, 192: 000–000.

The lack of a well-characterized, effective, and safe mucosal adjuvant is a serious problem in the development of efficacious mucosal vaccines (1–3). Most vaccine adjuvants are known to target innate signaling pathways that control the development of adaptive humoral and cellular immune responses, but the molecular mechanism of their action is still being characterized (4–10). Activation of TLRs has emerged as central to innate immune activation with various adjuvants, such as monophosphoryl lipid A and CpG oligonucleotides (7, 11–13). However, the importance of TLR signaling in the Ab responses was challenged recently (14). Additionally, it is unclear how these adjuvants function on mucosa, because mucosal tolerance may interfere with TLR-mediated innate receptor activation (15).

TLRs activate multiple signaling pathways, and their signaling is largely dependent on the MyD88 adaptor molecule, induction of stress-activated protein kinases, and the transcription factor NF-κB (7, 16). This leads to the expression of various cytokines and costimulatory molecules and maturation of dendritic cells (DCs), which are critical for the initiation of adaptive immunity. DC maturation involves upregulation of the costimulatory CD40, CD80, CD86, and MHC class II surface molecules and IL-12 cytokine expression (17). TCR engagement and receptor–ligand interactions via CD40/CD40L, CD80/CD86, and CD28/CTLA-4 families of costimulatory molecules are critical for priming of naive CD4 T cells, regulation of T and B cell responses, and induction of adaptive immunity (13, 18). However, little is known about the effects of non-TLR ligand–based adjuvants on DC maturation and costimulatory molecule expression or about the IL-12/IL-4 cytokine milieu that influences T cell differentiation into distinct Th-1 and Th-2 subsets (19–22). Adjuvants, such as aluminum salts (alum) or MF59, were reported to be independent of TLR signaling, with alum, but not MF59, inducing Nalp3 inflammasome activation. However, the significance of these findings to adjuvant activity remains open to debate (23–26). Also, no TLR-based adjuvant appears to consistently produce a Th-17...
response, which is now thought to be important in protecting mucosal surfaces during infection (27–30). This suggests that activation of other mechanisms may be important, particularly on mucosal surfaces.

We recently developed a mucosal nanoemulsion (NE) adjuvant, W80SEC, that does not contain known TLR or other innate receptor ligands but is able to enhance both humoral and cellular immunity (27, 31, 32). This NE adjuvant is simply an oil-in-water formulation of emulsified, highly refined soybean oil combined with nonionic and cationic surfactants and ethanol, and it is similar in size to many viruses that infect the nasal mucosa (32). Our studies (32–34) showed that nasal administration of the NE adjuvant mixed with Ag(s) induces robust mucosal and systemic Ab responses and unique Th1–biased and Th17–mediated cellular immunity without causing acute inflammation in the nasal mucosa. NE-based vaccines formulated with various viral and bacteria-derived Ags and administered intranasally (i.n.) produced protective immunity to a variety of pathogens, including anthrax, vaccinia, HIV, influenza, and hepatitis B surface Ag (32–35).

Materials and Methods

Adjuvant and Ag

The cationic W80SEC NE was formulated with materials “generally recognized as safe,” was manufactured under good manufacturing practices, and was supplied by NanoBio (Ann Arbor, MI). W80SEC NE contains Tween 80 (5%), ethanol (8%), cetyl pyridinium chloride (1%), soybean oil (64%), and water and is emulsified into droplets with a mean diameter of 400 nm using a high-speed emulsifier (32). The endotoxin content in the W80SEC formulation is less than 64%, and water and is emulsified into droplets with a mean diameter of 400 nm using a high-speed emulsifier (32). The endotoxin content in the W80SEC formulation is less than 64%, and water and is emulsified into droplets with a mean diameter of 400 nm using a high-speed emulsifier (32).

Reagents

PBS was purchased from Cellgro (Mediatech, Plainfield, NJ). Deionized water was prepared using a Milli-Q ultrapure water purification system (Millipore, Billerica, MA). Endotoxin-free water from InvivoGen (San Diego, CA) was used for all NE dilutions and vaccine preparations. BSA was purchased from Sigma (St. Louis, MO). LPS, polymyxin B (PMB), PMA, and ionomycin were purchased from InvivoGen (San Diego, CA). Alkaline phosphatase (AP)-conjugated rabbit anti-mouse IgG (H+L) and subclass-specific secondary Abs were purchased from Rockland Immunochemicals (Gilbertsville, PA).

Cells

Recombinant human HEK293-TLR-Blue clones and mouse RAW-Blue cells with a reporter plasmid expressing enzyme secretory embryonic AP (SEAP), under the control of an NF-κB/AP1-inducible promoter, were purchased from InvivoGen. Cells were maintained in DMEM containing Zeocin and blasticidin, according to the manufacturer’s recommendation. Mouse JAWS II DC and RAW264.7 macrophage cell lines were purchased from American Type Culture Collection (Manassas, VA) and cultured in conditions recommended by American Type Culture Collection.

TLR screening

TLR screening was performed using a panel of HEK293-TLR-Blue clones engineered to express only a single specific TLR and a SEAP–reporter plasmid activated with NF-κB, AP-1, and IRF7 transcription factors. Initial TLR ligand screening was performed by InvivoGen. Cells incubated with TLR-specific ligands were used as a positive control. Cell activation was evaluated as an increase in SEAP activity measured as absorbance at OD450 nm, using QUANTI-Blue reagent (InvivoGen), according to the manufacturer’s protocol.

Detection of NF-κB activation

To obtain nuclear and cytoplasmic extracts, 10⁷ JAWS II DCs or RAW264.7 cells were incubated in complete RPMI 1640 medium for 60 min at 37°C with subcytotoxic NE concentrations (0.001 or 0.01%), LPS (1 μg/ml), or PMA/ionomycin (200 ng/ml PMA and 1 μg/ml ionomycin). Cells were collected on ice, and cytosolic and nuclear extracts were prepared as described previously (38). For Western blots, 5 μg nuclear extracts was denatured and resolved on 4–12% PAGE-SDS and transferred onto Immobil-P membrane (Millipore). After blocking with 5% dry milk in PBS, TLR screening was performed with rabbit anti-p-p65/p-p50 (Epitomics, Burlingame, CA), anti–p-p65 (Santa Cruz Biotechnology, Santa Cruz, CA), and either anti–β-actin (Mouse Reactive Antibodies, Littleton, CO) or Cell Signaling Technology Abs, using the manufacturers’ recommended conditions, and developed with AP substrate (NBT/BCIP, Thermo Scientific, Waltham, MA).

Microarray analysis

JAWS II DCs (10¹ cells/culture) were incubated with 0.001% W80SEC alone (NE) or mixed with 10 μg/ml PA (PA-NE). Control cultures either were left untreated (PBS) or incubated with 10 μg/ml PA (PA) or with 1 μg/ml LPS 124 lamp LPS K12. Total cellular RNA was isolated from cells after 6 and 24 h of treatment using RNeasy (QIAGEN, Valencia, CA). RNA was evaluated for integrity, and microarray analysis of >45,000 probe sets was performed using Affymetrix Mouse GeneChip 430 2.0. The University of Michigan Comprehensive Cancer Center Microarray Core Facility. Gene transcription was analyzed using Biocomputer open access software and National Institutes of Health DAVID annotation program (39). Gene-expression data have been submitted to the Gene Expression Omnibus database under accession number GSE51804 (http://www.ddt.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51804).

RT-PCR assays

Gene-expression validation analysis was performed with real-time RT-PCR. The mRNA was isolated from JAWS II DCs, as described above, RT-PCR amplification was performed using the RT² First Strand Kit, RT² Profiler PCR Array (PAMM-225ZA) with 84 mouse genes involved in the NF-κB–signaling cascade, and RT² SYBR Green qPCR Master Mix (all from SABiosciences, Qiagen, Frederick, MD). The PCR array was run on the Eppendorf realplex2 Mastercycler ep gradient S. Data analysis was performed using the DDCT method (40). The fold-change for each gene from the control to the experimental group was calculated as 2^(DDCt).

Preparation of human monocyte-derived DCs

Human PBMCs were isolated from healthy donors, as described in Kryczek et al. (41). CD14⁺ monocytes were purified using paramagnetic beads (STEMCELL Technologies, Vancouver, BC, Canada) to >91% purity. Monocyte-derived DCs (MDDCs) were differentiated from CD14⁺ cells by incubation with 20 ng/ml GM-CSF and 5 ng/ml IL-4. On day six, the resulting DCs had uniform CD14⁺, CD80, CD86, and CD11c⁻ phenotype and morphology confirmed by flow cytometry (41).

In vitro activation of DCs

MDDCs (cultures (2 × 10⁶ cells/ml) were incubated for 48 h with 0.0001 and 0.001% W80SEC NE. Control cells were left untreated (PBS) or were incubated in the presence of PMA/ionomycin (200 ng/ml PMA and 1 μg/ml ionomycin). Phenotypic analysis of surface markers was performed by staining with FITC- and/or PE fluochrome–conjugated mAbs to HLA DR, CD80, and CD86 and with appropriate isotype controls (BD Biosciences, BD, San Jose, CA), according to the manufacturer’s protocol.
Cells were analyzed using an LSR II flow cytometer with DIVA software (both from BD).

**Animals**

Female MyD88<sup>−/−</sup> knockout C57BL6 mice were bred at the Unit for Laboratory Medicine facility at the University of Michigan. The MyD88<sup>−/−</sup> mutant genotype was obtained by insertion of a neomycin cassette sequence in place of exons 4 and 5. Genotype of knockout mice was confirmed by genomic PCR using primers specific to intron 2 and neomycin cassette sequences (42). TLR2<sup>−/−</sup>, TLR4<sup>−/−</sup>, CDS6<sup>−/−</sup>, double CD80/CD86<sup>−/−</sup> mutants, and wild-type (WT) C57BL6/6 background mice (females, 6–8 wk old) were purchased from The Jackson Laboratory (Bar Harbor, ME), CD40<sup>−/−</sup>, IL-12 p35/p40<sup>−/−</sup>, and IL-12Rβ1<sup>−/−</sup> knockout mice generated in two other reporter cell lines that naturally express a broad range of TLRs: RAW-Blue mouse macrophages (Fig. 1B) and THP-1–Blue human monocyte cells (Supplemental Fig. 1A). NE-mediated cell viability was tested in vitro. To rule out that NE-adjuvant activity was due to cellular or cytotoxic effects, we used a panel of gene expression changes in vitro. DCs were incubated with either W805EC (NE) alone or mixed with PA protein (PA-NE) as a prototype Ag. The i.m. immunizations consisted of 50 µl injected into mouse axillary muscle using a 26G 5/8 needle. Both i.m. and i.n. immunizations were performed in mice anesthetized with isoflurane using the IMPAC 6 anesthesia delivery system.

**Immunization procedures**

Vaccine formulation containing 20 µg PA admixed with 20% W805EC (PA-NE) was prepared by mixing Ag solution with concentrated W805EC in PBS as diluent. Mice (n = 5) were immunized with two i.n. administrations of either PA-NE or control formulation PA-PBS 4 wk apart. The i.m. immunizations (5 µl/mouse) were done using a micropipette tip applied to the nares while animals slowly inhaled the material. In some experiments, mice were immunized with i.m. injection of 20 µg PA adsorbed onto 500 µg aluminum hydroxide (PA-Alum). The i.m. immunizations used to determine activation of NF-κB by W805EC NE occurred from occult microbial contamination, we attempted to block activation using the LPS inhibitor PMB (45, 46). PMB treatment inhibited LPS-mediated activation but had no effect on NF-κB activation with NE (Fig. 1B, Supplemental Fig. 1B), suggesting that microbial contamination is not responsible for NE adjuvant activity. The lower SEAP levels at 0.01% NE are due to the cytotoxic effects of NE reducing cell viability in vitro. Furthermore, in vitro binding studies in RAW264.7 cells showed that NE does not interfere with LPS binding, suggesting that the LPS/MD-2/TLR4 binding site is not blocked by NE interactions (Fig. 1C, Supplemental Fig. 1C). These results suggest that the NE droplets may interact with cell membrane components, causing TLR activation followed by downstream TLR-signaling events (47). Western blot was used to determine activation of NF-κB subunits in either JAWS II DCs or RAW264.7 macrophage cells treated with W805EC NE (Fig. 1D, Supplemental Fig. 1D). W805EC treatment increased phosphorylation and nuclear translocation of p50 and p65 NF-κB subunits similar to PMA/ionomycin and LPS stimulation (Fig. 1D, upper panel). The mechanism of p50 and p65 activation involved degradation of the cytoplasmic IκBα (Fig. 1D, lower panel).

**Differential gene expression with W805EC NE and TLR4 agonist**

JAWS II DCs were used to further evaluate the immunostimulatory ability of W805EC NE by analysis of global gene expression changes in vitro. DCs were incubated with either W805EC (NE) alone or mixed with PA protein (PA-NE) as a prototype Ag. Control cultures were incubated with PA (PA) alone, stimulated with LPS (a TLR4 ligand), or with the addition of PBS (untreated). Cells were harvested after 6 or 24 h, and RNA was prepared for transcriptional analysis using mouse whole-genome microarray. Table I presents the number of gene transcripts changed with W805EC NE and LPS treatment in comparison with unstimulated controls (PBS-only treatment). At 6 h, >93% of the transcripts that were increased with NE or PA-NE treatments were common with the LPS treatment group (Fig. 2A). A divergent pattern of gene expression emerged at 24 h, showing only 20% transcripts that were common for W805EC and LPS treatments (Fig. 2B). The effect of W805EC on gene expression did not reflect a delayed pattern of LPS activation, because only 16.3% of genes modulated with NE at 24 h were common with those activated at the earlier time point with LPS (Fig. 2C). These results show the similarity of early W805EC NE effects and TLR4 activation. However, downstream molecular pathways are significantly different from those observed with LPS activation. Hierarchical clustering and functional analysis identified a significantly enriched category of defense immunity and cytokine activity GO:00051125 and difference in NF-κB pathway genes (Supplemental Fig. 2A, Supplemental Table I). Validation of the microarray findings was carried out using RT-PCR assays performed on a panel of NF-κB–signaling targets. This showed a pattern of gene upregulation consistent with LPS activation and the results from the microarray assay. W805EC induced early activation of Csf3, Cxcl3, Cxcl10, Cxcl11, Cxcl14, Cxcl16, and Cxcl20.
IL-1α, IL-1β, and IL-6 expression in a pattern that was similar, although at much lower levels, to that detected in LPS-treated JAWS II cells (Fig. 2D, 2E). Also, consistent with the microarray results, PA alone did not activate transcription (Supplemental Fig. 2B).

Role of TLR pathway in the mechanism of W805EC NE adjuvant in vivo

Based on in vitro results, we directly addressed the role of TLR signaling in W805EC NE adjuvanticity in vivo. MyD88−/− mice (deficient in a common TLR adaptor protein), TLR2−/− and TLR4−/− mice (lacking expression of either one of these TLRs), and WT mice were immunized i.n. with either PA-NE or PA-PBS or i.m. with PA-Alum. Serum anti-PA IgG titers did not reveal any discernible difference between all three mutant mice and WT controls (Fig. 3A, 3B). Specifically, W805EC adjuvant produced similar anti-PA IgG titers in MyD88−/−, TLR2−/−, TLR4−/−, and WT mice, indicating that the innate TLR-MyD88 pathway is not required for the Ab response with mucosal administration of NE adjuvant. Furthermore, both MyD88−/− and WT animals had an Ab response that was equal to control mice immunized i.m. with alum adjuvant (Fig. 3A). Nasal immunization of germ-free mice demonstrated that activity of W805EC NE adjuvant also was not dependent on the presence of microbial components derived from normal commensal mucosal flora, because Ab titers in these animals were comparable to those obtained after parenteral immunization with alum adjuvant (Fig. 3C).

In contrast, analysis of cellular immunity demonstrated that MyD88 deficiency significantly affects the ability of W805EC NE to mount the balanced Th-1 and Th-2 Ab response demonstrated by WT animals (Fig. 4A). Ag-specific stimulation of WT splenocytes produced strong IFN-γ expression, which was severely reduced in MyD88−/−, TLR2−/−, and TLR4−/− mutants (Fig. 4). Furthermore, analysis of the IgG subclass pattern in MyD88−/− mice showed increased IgG1 and decreased IgG2b...
subclass titers (Supplemental Fig. 3A). A comparison of the Th-type pattern of cytokine expression in splenocytes from WT mice immunized with either PA-NE (i.n.) or PA-Alum (i.m.) clearly documents differences in the type of Th polarization of the cellular response. These data show high levels of the Th-1–type cytokines IFN-γ and IL-2 and low levels of the Th-2 type cytokines IL-5 and IL-13 in mice immunized with NE adjuvant. In contrast, mice immunized with alum, a classic Th-2–type adjuvant, produce characteristically high levels of IL-5 and IL-13 in mice immunized with NE adjuvant. In contrast, mice immunized with alum, a classic Th-2–type adjuvant, produce characteristically high levels of IL-5 and IL-13 in mice immunized with NE adjuvant. MyD88−/−, TLR2−/−, and TLR4−/− splenocytes were fully capable of IFN-γ secretion upon activation with PMA/ionomycin in vitro, indicating that reduction of IFN-γ is not due to an intrinsic defect in the expression of the IFN-γ gene (data not shown). Induction of the Th-17 response and IL-17 expression were completely abrogated in W805EC NE–immunized MyD88−/− mice (Fig. 4A), as we (27) showed previously in TLR2−/− and TLR4−/− mutants. MyD88 and TLR2 deficiency resulted in dominant Th-2 cellular immunity, with a significant increase in IL-5 and IL-13, as well as regulatory IL-10 cytokine, whereas TLR4−/− splenocytes pro-
duced lower induction of these cytokines than did TLR2−/− mutants (Fig. 4B). Ag-specific expression of GM-CSF was not affected by the absence of MyD88 signaling. No Ag-specific cytokine secretion was observed in nonimmunized control splenocytes derived from any strain of mice.

W805EC NE induces upregulation of DC maturation markers in vitro

To assess the capability of W805EC NE to activate DC maturation, we evaluated the NE biological effect on human MDDCs. Analysis of the cell surface phenotype in these cells demonstrated that NE produced a consistent increase in DC maturation markers and costimulatory molecule expression (Fig. 5). MHC class II expression increased ∼2-fold when incubated with 0.001% NE, but it was unchanged at the lower concentration (Fig. 5, left panels). Furthermore, the population of either CD80 or CD86 (Bright) DCs increased ∼2-fold at both NE concentrations (Fig. 5, middle and right panels). In general, the effect of W805SEC NE on DC maturation phenotype was comparable to protein kinase C stimulation used as a positive control (Fig. 5, bottom panels).

W805EC NE adjuvant activity in mice deficient in CD80, CD86, and CD40 costimulatory molecules

Activation and upregulation of immunostimulatory surface molecules on DCs and other APCs are critical check points for the initiation of Ag-specific adaptive immune responses (48). To investigate the requirement for costimulatory receptors in the mechanism of W805EC adjuvant, CD86−/−, double CD80/CD86−/−, and CD40−/− mutant mice were immunized i.n. with PA-NE or a PA-PBS control. Serum IgG analysis showed that mice lacking CD86 expression had an Ab response on par with WT animals, whereas double CD80/CD86 and CD40 mutants failed to produce anti-PA Abs (Fig. 6A). Induction of cellular immunity was assessed by Ag-specific cytokine expression in splenocytes. Results demonstrate severely diminished production of Th-1–type cytokines IFN-γ and IL-2 in CD86−/− and CD40−/− mutants, whereas no Th-1– or Th-2–type cytokines were detected in CD80/CD86−/− mutants (Fig. 6B). In contrast, CD86-deficient splenocytes produced elevated levels of Th-2–type cytokine IL-5, whereas IL-5, IL-10, and IL-13 were diminished in CD40−/− mutants (Fig. 6B). These results suggest that the W805EC adjuvant may independently use CD80 and CD86 signaling and that CD80 compensates for the CD86 deficiency in the Ab response; however, it is not sufficient to maintain Th-1–biased cell immunity. Lack of both CD80 and CD86 molecules abrogated the immune response with the NE adjuvant. Similarly, the profound effect of the CD40−/− mutation on both Ab and cellular responses demonstrates the critical and nonredundant role of this costimulatory molecule in the mechanism of W805EC NE adjuvant activity.

FIGURE 3. W805EC NE adjuvant does not require TLR-MyD88 signaling to induce Ab response. Comparison of IgG titers in MyD88−/− (A) and TLR2−/− and TLR4−/− (B) mutants immunized i.n. with PA-NE, PA-Alum, or PA-PBS. (C) Comparison of IgG titers in normal and germ-free Swiss-Webster mice. Anti-PA IgG Ab titers were measured at 11 wk after primary immunization. Experiments were performed twice, with five animals/group.
W805EC NE adjuvant activity in IL-12− and IL-12Rβ1−/− deficient mice

IL-12, a cytokine secreted mainly by activated APCs, is a potent stimulator of T cell function and polarization toward Th-1 immunity (49). We investigated the role of IL-12 signaling in NE adjuvant activity using mice deficient in both p35 and p40 IL-12 subunits (IL-12 p35/p40−/−), as well as in mutants lacking cognate IL-12Rβ1 (IL-12Rβ1−/−). Mice were immunized i.n. with PA-NE and with PA-PBS as control. Serum IgG analysis showed that IL-12 p35/p40−/− mutants produced ∼15-fold lower Ab titers than did WT mice, whereas the lack of IL-12Rβ1 had no significant effect on the Ab response (Fig. 7A). T cell immunity assessed in vitro by analysis of Ag-specific cytokine expression in splenocytes from mutant mice showed that both mutants failed to produce Th-1−type cytokines and IL-17, whereas levels of IL-5 and IL-13 Th-2 cytokines were elevated in comparison with WT mice (Fig. 6B–D). These results demonstrate that W805EC NE adjuvant does not require an IL-12− environment to elicit robust IgG responses. However, IL-12 and downstream signaling via the IL-12Rβ1 receptor are necessary for activation and for maintenance of Th-1−balanced and Th-17−type cellular immunity (27).

Discussion

Vaccine adjuvants are composed of diverse classes of materials that have poorly characterized mechanisms of action, although many of these compounds contain components that activate inflammation and innate immunity (10, 14). Some adjuvants are known to contain biological ligands of TLR that activate the innate response and induce humoral and cellular adaptive immunity (10, 14, 50–52). Other materials, like squalene, have been formulated in oil-in-water emulsions (such as M59 adjuvant) as candidates for human vaccine, but they have no known mechanism of action for their proinflammatory activity (53).

In this article, we present data on a novel NE adjuvant, W805EC NE, which is one of the first effective mucosal-acting adjuvants and does not contain specific proinflammatory or biological materials. Despite this, the mechanism of this NE adjuvant appears to involve both TLR-dependent and TLR-independent pathways for induction of adaptive humoral and cellular immunity.

In comparison with other emulsion-based adjuvants, W805EC NE is a simple formulation of four components: highly refined, heat-treated soybean oil, nonanionic Tween 80 and cationic cetyl pyridinium chloride surfactants, and ethyl alcohol, all emulsified in water to obtain a dispersion with a nanoscale lipid droplet size.
NE’s unique mucosal adjuvant activity appears to be derived both from the high potential energy of this nanostructure that facilitates fusion with cells, as well as from its chemical composition (32, 54). Fusion of the emulsion with DCs in vitro induces IkB degradation and subsequent activation of p50 and p65 NF-κB subunits. The activation results also were confirmed in THP-1Blue and RAW-Blue NF-κB reporter lines and in DCs and macrophages transiently transfected with a different reporter plasmid expressing luciferase under control of a minimal NF-κB–inducible promoter (pNF-κB–Luc, Stratagene; data not shown). The ability to directly mediate NF-κB activation in various types of immune cells could be central to the NE mechanism of immunostimulation, because NF-κB functions as a pleiotropic regulator and transducer of the stimulatory signals for genes involved in a variety of immune responses (55–57).

Cell-based screening for TLR agonist activity and global analysis of gene expression suggest that W805EC NE activity involves innate receptors TLR2 and TLR4 (Figs. 1A, 4). Although NE requires these receptors, it does not compete with the LPS for TLR binding, indicating that NE may activate TLR by nonligand-specific interactions; this could include aggregating receptors in lipid rafts, as is documented for TCR signaling (58, 59). In addition, the microarray analysis of global gene expression suggests that W805EC NE appears to use TLR4 to initiate signaling pathways, but its downstream signaling appears to be distinct from LPS, at least from the resulting gene-activation patterns. Of interest, alum adjuvant also was reported to interact with DC membrane components to trigger DC signaling and promote CD4+ T cell activation and humoral immune responses (60). In contrast, the absence of TLR-MyD88 signaling has a profound effect on NE-induced cellular immunity. Our data also suggest that, in W805EC NE–immunized mice, TLR2 and TLR4 differentially affect the Th-1/Th-2 balance, because TLR4−/− and MyD88−/− mice had severely diminished Th-1– and Th-17–type cytokine production and reduced IgG2b Ab titers, whereas Th-1 cytokines in TLR2-deficient mice were affected to a lesser degree (27). Furthermore, the absence of TLR2 and MyD88 resulted in the elevated expression of IL-5, IL-10, and IL-13 cytokines, despite functional TLR4. In contrast to our results, when TLR2-deficient mice are used in a rheumatoid arthritis model or immunized with the YF-17D yellow fever vaccine, these animals have enhanced Th-1 immunity (68–70). Although previous reports indicated that MyD88−/− mice develop Th-2 responses during Chlamydia infection and are protected from Th-1–type experimental autoimmunity (experimental autoimmune encephalomyelitis) (71, 72), distinct roles for TLR2- and TLR4-activating adjuvants have not been clearly defined (73). It is possible that this
nuanced response reflects relative contributions of TLR2 (MyD88-dependent) and TLR4 (using both MyD88 and TRIF) activation with W805EC adjuvant. Additional studies using animals with double TLR2/TLR4 or MyD88/TRIF defects will help to clarify the role of MyD88-dependent and -independent innate signaling in the mucosal mechanism of W805EC NE.

In addition to TLR activation, DCs and IL-12 signaling play a critical role in the development of cell-mediated immunity (49, 74, 75). Consistent with other studies, our results show that IL-12 (p35/p40) and IL-12Rβ1 receptor are required for NE-mediated Th-1–skewed T cell responses. However, because both IL-12–induced IFN-γ production and T cell proliferation are impaired in either IL-12 or IL-12Rβ1 mutant mice, it is not entirely clear whether NE-mediated cellular responses depend solely on IL-12 cytokine expression or also require downstream signaling by IFN-γ (76). In addition, because IL-12 mutants do not produce IFN-γ in response to LPS-TLR4 stimulation, lack of Th-1 immunity suggests that NE’s effects on DC activity, and subsequent naive T cell priming, may be mediated by TLR4 and/or IFN-γ. The absence of an IL-17 response in IL-12p35/40-deficient mutants is most likely due to a dual role for IL-12p40 as a common component with IL-23, which drives Th-17 differentiation. Our results also suggest that NE activity may link IL-12 and MyD88 for the activation of mTOR to promote Th-17 via IL-1 and IL-23 signaling (77, 78). Similar to the TLR-MyD88 deficiency, lack of either IL-12 or IL-12Rβ1 had no detrimental effect on Ab responses with NE adjuvant. Taken together, these results demonstrate that W805EC NE adjuvant mediates a balanced cellular response involving both IL-12–dependent Th-1 and Th-17 cellular immunity and IL-12–independent humoral immunity, a process that is fundamentally different from the activity of alum adjuvant (79–81).

Multiple molecular signals are required for the development of an adaptive immune response. Ag presentation to the cognate TCRs or BCRs by APCs is the primary signal; however, the engagement of costimulatory molecules by APCs and T and B lymphocytes is also important (18). CD80, CD86, and MHC class II molecules are expressed by mature DCs, monocytes/macrophages, and B cells, and they modulate naive CD4+ T cell functions by binding with CD28 or CTL-4 receptors (17). Recently, our group (36, 37) demonstrated that nasal administration of W805EC NE adjuvant to mucosal surfaces increased Ag uptake and trafficking by epithelial cells and DCs, resulting in DC maturation. The current studies showed that W805EC induced DC maturation in vitro, character-
ized by the increased expression of B7 family molecules CD80 and CD86, as well as MHC class II (82, 83). CD80 and CD86 share ~27% external domain homology and activate the bidirectional signaling by engaging either the immunostimulatory CD28 or the inhibitory CTLA-4 receptors on T cells (18, 84). Consistent with other studies, mice lacking CD86 produced normal Ab titers, whereas double CD80/CD86 mutation completely abolished this response and severely reduced a Th-1 bias of immunity (85, 86). This suggests that NE activates either CD80 or CD86 signaling, and CD80 activation alone is sufficient for the B cell–dependent IgG response but not for Th-1–type cell immunity. In addition to diminished Th-1–type responses, all investigated mutations severely repressed development of Th-17 immunity after immunization with NE adjuvant, as demonstrated in our previous study (27).

In summary, we identified a unique set of signaling activities underlying the mechanism of the mucosal adjuvant W805EC NE (Table II). Activation of TLR through nonligand-mediated means and signaling through MyD88 and IL-12 pathways are indispensable for the induction-balanced Th-1 and Th-17 cellular immunity, but they are not necessary for an Ab response. Because of the unique activity of this material as a mucosal adjuvant, we believe that these data have important implications for understanding the signaling pathways involved in mucosal immunity. In addition, understanding the separate mechanisms by which W805EC NE adjuvant produces humoral and cellular types of immune responses will further facilitate the rational development of the most effective mucosal vaccines.

Table II. Summary: immunological checkpoints of Ab and cellular immune responses induced with W805EC NE mucosal adjuvant

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Humoral</th>
<th>Adaptive Immune Responses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ab</td>
<td>Th-1</td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MyD88−/−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>TLR2−/−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>TLR4−/−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>IL-12−/−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>IL-12Rβ1−/−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>CD40−/−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>CD86−/−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>CD86/CD86−/−</td>
<td>+</td>
<td>−</td>
</tr>
</tbody>
</table>

* and − signify induction of immune response.
Acknowledgments
We thank Dr. Ilona Kryczek for assistance with FACS analysis and evaluation of NE’s effect on costimulatory molecule expression in MDCDCs and Dr. Wendy Banka for help with preparation of the manuscript.

Disclosures
J.R.B., Jr. has an ownership stake in NanoBio Corp., the company that the University of Michigan has licensed to commercialize the NE technology examined in these studies. NanoBio Corp. was also paid under a contract to produce the formulations used in these studies. NanoBio Corp. had no role in the design of the studies, the data collection and analysis, the decision to publish, or the preparation of this manuscript. The other authors have no financial conflicts of interest.

References

Downloaded from http://www.jimmunol.org/ by guest on August 31, 2017

The Journal of Immunology

11:1


